Welcome to our dedicated page for REGENCY CENTERS SEC filings (Ticker: REG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on REGENCY CENTERS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into REGENCY CENTERS's regulatory disclosures and financial reporting.
Regency Centers filed a notice under Rule 144 for a planned sale of restricted shares. The filing covers the potential sale of 26,000 shares of common stock through Merrill Lynch on NASDAQ, with an aggregate market value of 1,958,060 at the time indicated.
The shares were originally acquired from Regency Centers on 02/14/2025 as a stock bonus, meaning they were granted as compensation rather than purchased for cash. The filing states that the person for whose account the securities are to be sold represents that they are not aware of undisclosed material adverse information about the company’s current or prospective operations.
Regency Centers Corporation reported that director C. Ronald Blankenship has informed the company he will not stand for re-election and will retire from the Board of Directors. His retirement will be effective at the end of his current term, immediately following the company’s 2026 Annual Meeting of Shareholders.
The company states that Mr. Blankenship’s decision is not due to any disagreement regarding operations, policies, or practices. The Board and management expressed deep appreciation for his 25 years of service and highlighted his leadership, business judgment, and counsel to the organization.
Regency Centers reported strong fourth quarter and full-year 2025 results and issued 2026 guidance. Net income attributable to common shareholders rose to $199.1 million, or $1.09 per diluted share in Q4, up from $0.46 a year earlier, and to $2.82 per share for 2025 versus $2.11 in 2024.
2025 Nareit FFO was $855.7 million, or $4.64 per diluted share, and Core Operating Earnings were $4.41 per share, both higher than 2024. Same property NOI excluding termination fees grew 4.7% in Q4 and 5.3% for the year, with the same property portfolio 96.5% leased at year-end and cash rent spreads above 10% on 6.8 million square feet of 2025 leasing.
The company started about $318 million of development and redevelopment projects and completed roughly $212 million, while acquiring about $538 million of shopping centers. Pro‑rata net debt and preferred stock to operating EBITDAre was 5.1x. The board declared a quarterly common dividend of $0.755 per share. For 2026, Regency guides to net income of $2.35–$2.39 per diluted share, Nareit FFO of $4.83–$4.87 per share, Core Operating Earnings of $4.59–$4.63 per share, and same property NOI growth of 3.25%–3.75%.
Regency Centers director C. Ronald Blankenship received 481 shares of common stock on February 4, 2026, coded as an acquisition. A footnote explains this represents director fees paid in stock under Regency’s Omnibus Incentive Plan. Following this award, he directly owns 112,351 common shares.
Regency Centers director Peter Linneman reported a routine stock-based compensation transaction. On February 4, 2026, he acquired 357 shares of common stock coded as an "A" (award) transaction. These shares represent director’s fees paid in stock under Regency’s Omnibus Incentive Plan. Following this award, he beneficially owns 53,600 shares of Regency Centers common stock held directly.
Regency Centers Corp director Karin Klein reported a stock-based compensation grant. On February 4, 2026, she acquired 428 shares of Regency Centers common stock, reported at a price of $0.00 per share, as director fees paid in stock under Regency's Omnibus Incentive Plan.
Following this grant, Klein beneficially owns 23,198 shares of Regency Centers common stock in direct ownership form. The filing reflects a routine equity compensation award rather than an open-market purchase or sale.
Regency Centers Corporation executive Nicholas Andrew Wibbenmeyer, West Regional President & CIO, reported an equity grant on a Form 4. He received 4,414 shares of restricted stock on February 3, 2026 at a stated price of $0 per share.
The filing shows he now beneficially owns 4,414 derivative securities, held directly. According to the footnote, these restricted shares vest 25% per year beginning February 3, 2027, meaning the award becomes earned gradually over four years.
Regency Centers Corp. executive Alan Todd Roth, Eastern Regional President and Chief Operating Officer, reported an equity award in the form of a restricted stock grant. On February 3, 2026, he received 4,414 restricted shares of common stock at a price of $0 per share, held directly.
The award is subject to a time-based vesting schedule. According to the footnote, the shares vest 25% per year beginning February 3, 2027, meaning the grant becomes fully vested over four years if the conditions are met.
Regency Centers Corp executive vice president and chief financial officer Michael J. Mas reported receiving a restricted stock grant of 5,601 derivative securities on February 3, 2026. These shares vest 25% annually beginning on February 3, 2027. Following this grant, he beneficially owns 5,601 shares directly.
Regency Centers Corp disclosed that Executive Chairman and director Martin E. Stein Jr. received a grant of 2,069 shares of restricted stock on February 3, 2026. The award was granted at a price of $0 per share and is held directly.
The restricted shares are scheduled to vest in four equal installments of 25% per year, beginning on February 3, 2027. Following this grant, Stein beneficially owns 2,069 derivative securities linked to Regency Centers common stock.